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The SSRs Cre (causes recombination of the bacterio-
phage P1 genome) and Flp (named for its ability to invert,
or “flip,” a DNA segment in S. cerevisiae) are able to
recombine specific sequences of DNA with high fidelity
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without the need for cofactors (reviewed in Stark et al.,
1992; Dymecki, 2000). For this reason, they have been
used effectively to create gene deletions, insertions, in-
Site-specific recombinase systems (Cre-loxP, Flp- versions, and exchanges in exogenous systems such
FRT, andφC31-att) are transforming both forward and as flies (Golic and Lindquist, 1989; Dang and Perrimon,
reverse genetics in mice. By enabling high-fidelity DNA 1992; Xu and Rubin, 1993), mammalian cell culture
modifications to be induced in vitro or in vivo, these (Sauer and Henderson, 1988; O’Gorman et al., 1991),
systems have incited a wave of new biology, advancing and mice (Lakso et al., 1992; Orban et al., 1992; Dymecki,
our understanding of gene function, genetic relation- 1996). Cre and Flp recombine DNA at defined target
ships, development, and disease. sites, termed loxP (locus of crossover (x) in P1) (Hoess et
al., 1982) and FRT (Flp recombinase recognition target)
(McLeod et al., 1986), respectively, in both actively divid-
With the human genome project estimating over 30,000 ing and postmitotic cells, as well as in most tissue types.
genes, our task now is to determine the contribution of Cre and Flp, both members of the  integrase super-
each gene to development, disease, and disability. A family of SSRs, share a common mechanism of DNA
powerful method for inferring the role of human genes recombination that involves strand cleavage, exchange,
is to analyze the expression and function of homologous and ligation (Sadowski, 1995). Although distinct at the
genes in model organisms, such as the mouse. Nearly nucleotide level, loxP (Figure 1A) and FRT (Figure 1B)
every human gene has a counterpart in the mouse, and, sites share an overall structure which includes two 13
among genetic model systems, the mouse is unique in basepair (bp) palindromic sequences, or inverted re-
its applicability to human organogenesis, immunology, peats, separated by an 8 bp asymmetric core, or spacer,
neurobiology, reproduction, behavior, and epigenetics. sequence. In the presence of two target sites, recombi-
Thus, the mouse is an essential model system both nase monomers bound to the inverted repeats promote
for functionally annotating the human genome and for DNA synaptic complex formation and recombination be-
modeling human disease. tween the two sites (Figure 1C) (Hoess et al., 1985).
The level at which one may use the mouse to explore Strand cleavage, exchange, and ligation occur within
gene function is dependent, in part, upon the methodol- the spacers (Amin et al., 1991). Because of spacer asym-
ogies available to manipulate the genome. By providing metry, strand exchange is possible only when target
a means to delete, insert, invert, or exchange chromo- sites are connected by synapsis in one orientation
somal DNA with high fidelity, site-specific recombinase (Hoess et al., 1986). Consequently, the relative orienta-
(SSR) technology is revolutionizing mouse genetics. tion of target sites with respect to one another deter-
SSR technology is being applied to induce null muta- mines the outcome of recombination: Cre and Flp will
excise a circular molecule from between two directlytions in discrete cells in vivo, bypassing embryonic le-
repeated target sites (Figure 2A), integrate a circularthality associated with many germline null alleles. As a
molecule into a linear molecule each possessing a targetresult, investigations can now reach beyond the first
site (Figure 2A), invert the DNA between two invertedrequired function of a gene. Chemical mutagenesis
sites (Figure 2B), and exchange sequences distal to tar-screens and mapping studies are being facilitated by
get sites present on two linear molecules, such as a pairlibraries of deletions, duplications, and inversions—
of nonhomologous chromosomes (Figure 2C).reagents historically limited to Drosophila but now avail-
The excision reaction is effectively irreversible (dueable in the mouse by the application of SSR technology.
to loss of the circular reaction product) and has beenHuman diseases associated with chromosomal translo-
exploited most readily in the mouse. Indeed, it is thecations are being modeled in mice using SSR-based
basis for both conditional gene inactivation and molecu-genomic engineering. And finally, SSR technology is
lar fate mapping, tools that have allowed gene functionbeing applied to map the deployment of cells during
and cell deployment to be studied in the late embryoembryogenesis in order to reveal their contributions to
and adult (these applications are discussed further be-adult tissues and to provide a framework for analyzing
low). By contrast, stable insertion and inversion reac-genotype-phenotype relationships uncovered by muta-
tions that permit, for example, a sound comparison ofgenesis. In this review, we focus on how mouse genetics
phenotypic consequences of different DNA sequencesis being transformed through SSR technology. We begin
at a defined locus have been less straightforward toby discussing the current contents of the SSR “toolbox”
engineer. This is because, in each case, the recombina-and follow by presenting some new biology made possi-
tion product harbors two identical target sites in cis,ble through their application.
which are themselves substrates for recombination (i.e.,
excision or repeated inversions, respectively). With the
goal of being able to further modify an already targeted*Correspondence: dymecki@rascal.med.harvard.edu
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Figure 1. Cre and Flp Recombinase Target
Sites and Mechanism of Recombination
The Cre and Flp target sites each contain
two 13 bp inverted repeats flanking an 8 bp
asymmetrical core, or spacer (nucleotides of
the spacer are indicated in bold). Horizontal
arrows mark the inverted repeats and a trian-
gle the spacer. The graded sides of the trian-
gle represent the asymmetry of the spacer,
which imparts directionality on the target site
and which, in turn, imparts directionality on
the recombination reaction (see text). By con-
vention, nucleotides are numbered from the
center of the site.
(A) The Cre recombinase target site is termed
loxP. (B) The Flp recombinase target site is
termed FRT. An additional upstream 13 bp
repeat is present in the 2  plasmid but is
dispensable for Flp-mediated recombination,
making the minimal FRT site 34 bp. By con-
trast to a loxP site, the inverted repeats of
an FRT site contain a single bp difference
(underlined). (C) Synaptic complex formed
between recombinase molecules (Cre or Flp)
and two identical target sites (distinguished
here as being either black or white). One re-
combinase monomer binds each 13 bp re-
peat, while the spacer sequence provides the
site of strand cleavage, exchange (via a Holli-
day intermediate), and ligation. In the final
product, there is an exchange of DNA be-
tween the two starting sites.
or trapped locus, clever strategies have been devised to In RMCE, a selectable marker (such as a fusion gene
that permits both positive and negative selection)make insertions and inversions effectively irreversible.
Fundamental to these strategies is the finding that Cre flanked by heterotypic sites is inserted into a chromo-
somal site within the mouse embryonic stem (ES) celland Flp each tolerate certain variations in their target
sequences, but effectively recombine only particular genome by homologous recombination (thereby “tag-
ging” the site); a DNA sequence of choice is then in-combinations of these alternative sites.
Variant target sites for Cre and Flp fall into two classes: serted into the tagged site replacing the selectable
marker by an exchange step (Figure 3A). Cells in whichspacer variants and inverted-repeat variants (Table 1).
The first class contains nucleotide substitutions within the DNA swap has occurred are enriched by negative
selection. The final product is stable because left inthe spacer sequence and exploits the finding that it is
spacer length (8 bp), not sequence (Hoess et al., 1986; cis are heterotypic (incompatible) sites. The success of
RMCE, therefore, hinges on the inability of heterotypicSenecoff et al., 1988), that is critical for efficient recombi-
nation, so long as the sequence between participating SSR target sites to recombine with one another. For
Flp-mediated RMCE, the spacer variant F3 and F5 sitessites is identical (Senecoff and Cox, 1986). Recombina-
tion is therefore efficiently mediated between pairs of have proven impervious to recombination with a wild-
type FRT site (Schlake and Bode, 1994). Likewise, forhomotypic (e.g., FRT/FRT or F3/F3) but not heterotypic
(e.g., FRT/F3) sites. Such exclusivity is the basis of the Cre-mediated RMCE, the spacer variant sites lox2272
(Lee and Saito, 1998) and m2 (Langer et al., 2002) appearinsertion strategy called “recombinase-mediated cas-
sette exchange” (RMCE) (reviewed in Bode et al., 2000; impervious to recombination with a loxP site. By con-
trast, the alternative Cre target site lox511 (Bethke andBaer and Bode, 2001) and the inversion strategy called
the “FLEx” switch (Schnutgen et al., 2003). Sauer, 1997) (also termed L1 [Hoess et al., 1986]) has
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oriented sites (Figure 3B) (as such, FLEx stands for “flip
excision”). A DNA fragment to be inverted is flanked by
two pairs of matching heterotypic target sites. Recombi-
nation between either pair of homotypic sites results
in cassette inversion, including inversion of the interior
target site. This positions two homotypic sites in direct
orientation, resulting in immediate excisional recombi-
nation. The end product is an inverted cassette flanked
by two heterotypic sites that cannot recombine with one
another, thereby preventing further inversions.
The second class of alternative SSR target sites, the
inverted-repeat variants, is also being exploited to engi-
neer stable DNA insertions (Figure 4A) and inversions
(Figure 4B). Here, variant target sites contain nucleotide
substitutions within the inverted repeats that compro-
mise binding of the recombinase to DNA (Albert et al.,
1995, and Araki et al., 1997, for Cre; and Senecoff et
al., 1988, for Flp). A target site containing a nucleotide
substitution in the left inverted repeat (an LE mutant
site) can recombine with a site containing an analogous
substitution in the right inverted repeat (an RE mutant
site), albeit at a slower reaction rate. The recombination
product harbors one wild-type and one LE/RE doubly
mutant site, the latter being effectively inert. For stable
DNA insertions, this class of alternative SSR target sites
has typically been used for the incorporation of an in-
coming plasmid into chromosomal DNA (as depicted in
Figure 4A).
Further flexibility in SSR applications has arisen
through establishment of the Streptomyces phage-
derived φC31 SSR for use in ES cells (Belteki et al.,
2003). The φC31 SSR mediates recombination only be-
tween the heterotypic sites attB (34 bp in length) and
attP (39 bp in length) (Groth et al., 2000) (see Table 1).
attB and attP, named for the attachment sites for the
phage integrase on the bacterial and phage genomes,
respectively, both contain imperfect inverted repeats
that are likely bound byφC31 homodimers (Groth et al.,
2000). The product sites, attL and attR, are effectively
inert to further φC31-mediated recombination (Belteki
et al., 2003), making the reaction irreversible. For cata-
lyzing insertions, it has been found that attB-bearing
DNA inserts into a genomic attP site more readily than
an attP site into a genomic attB site (Thyagarajan et
al., 2001; Belteki et al., 2003). Thus, typical strategies
Figure 2. Recombination Reactions Mediated by Cre or Flp position by homologous recombination an attP-bearing
The relative orientation of target sites with respect to one another “docking site” into a defined locus, which is then part-
determines the outcome of the recombination reaction: Cre or Flp
nered with an attB-bearing incoming sequence forwill (A) excise a circular molecule from between two directly oriented
insertion (see Supplemental Figure S1 at http://www.target sites, integrate a circular molecule into a linear molecule each
developmentalcell.com/cgi/content/full/6/1/7/DC1).possessing a target site; (B) invert the DNA between two inverted
sites; and (C) exchange sequences distal to target sites present on Importantly, expression ofφC31 in ES cells (like Cre and
two linear molecules. This latter type of intermolecular recombina- Flp) is compatible with germline competence (Belteki et
tion can occur between target sites on nonhomologous chromo- al., 2003).
somes (indicated by the letters i and j) to produce a balanced translo- When designing experiments using φC31, an impor-
cation. Black and green lines represent chromosomal DNA, with
tant consideration is the presence of multiple pseudoorientation indicated by the letters a–d, or e–h; gray arrows indicate
attP sites (that is, sequences that are similar but notthe reversible nature of each reaction.
identical to the wild-type attP site) in the genomes of
both human and mouse cell lines (31 and 57 reported
been found to recombine, albeit at low efficiency (1%– [Thyagarajan et al., 2001] thus far, respectively). In cer-
5%), with a wild-type loxP site (Feng et al., 1999; Kolb, tain human and mouse cell lines, some of these endoge-
2001) and, thus, is less effective in RMCE reactions. nous pseudo attP sites appear capable of recombining
The FLEx switch strategy uses both wild-type and with incoming attB-bearing DNA, even in the presence
spacer variant target sites, and exploits the ability of of an engineered wild-type attP site (Thyagarajan et al.,
SSRs to invert a DNA sequence between opposing tar- 2001). Empirical evidence suggests, however, that these
pseudo sites do not confound targeted integrationget sites but delete a DNA sequence between similarly
Developmental Cell
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Table 1. Alternative SSR Recognition Sites
Use of Alternative
Target Sitea Inverted repeat 1 Spacer Inverted Repeat 2 Site Reference
loxP ATAACTTCGTATA ATGTATGC TATACGAAGTTAT Hoess, et al., 1982
lox511b ATAACTTCGTATA ATGTATaC TATACGAAGTTAT RMCEc Hoess, et al., 1986
Bethke and Sauer, 1997
lox5171 ATAACTTCGTATA ATGTgTaC TATACGAAGTTAT RMCE Lee and Saito, 1998
lox2272d ATAACTTCGTATA AaGTATcC TATACGAAGTTAT RMCE Lee and Saito, 1998
m2 ATAACTTCGTATA AgaaAcca TATACGAAGTTAT RMCE Langer, et al., 2002
lox71 taccgTTCGTATA ATGTATGC TATACGAAGTTAT Stable insertion or Albert, et al., 1995
(LEe mutant) inversion
lox66 ATAACTTCGTATA ATGTATGC TATACGAAcggta Stable insertion or Albert, et al., 1995
(REf mutant) inversion
FRT GAAGTTCCTATTC TCTAGAAA GTATAGGAACTTC McLeod, et al., 1986
F3 GAAGTTCCTATTC TtcAaAtA GTATAGGAACTTC RMCE Schlake and Bode, 1994
F5 GAAGTTCCTATTC TtcAaAAg GTATAGGAACTTC RMCE Schlake and Bode, 1994
FRT mutant 10 GAAGTTCaTATTC TCTAGAAA GTATAGGAACTTC Stable insertion or Senecoff, et al., 1988
(LE mutant) inversion
FRT mutant 10 GAAGTTCCTATTC TCTAGAAA GTATAtGAACTTC Stable insertion Senecoff, et al., 1988
(RE mutant) or inversion
attBg TCGAGTGAGGTGGAGTACGCGCCCGGGGAGCC RMCE or stable Belteki et al., 2003
CAAGGGCACGCCCTGGCACCCGCA inversion
attP CTAGACCCTACGCCCCCAACTGAGAGAACTCAAAGGT RMCE or stable Belteki et al., 2003
TACCCCAGTTGGGGCACG inversion
a Nucleotides that have been altered from the wild-type sites are lowercase.
b The alternative Cre target site lox511 (Bethke and Sauer, 1997) is also referred to as L1 (Hoess et al., 1986) and mutant 71 (Lee and Saito,
1998). lox511 can recombine, albeit at low efficiency (1–5%), with a wild-type loxP site and therefore may have limited use in RMCE reactions
(Kolb, 2001, and see text).
c RMCE, recombinase mediated cassette exchange.
d lox2272 is also referred to as lox2722 (Kolb, 2001).
e LE, left-hand element (LE) (inverted repeat 1) of SSR recognition site.
f RE, right-hand element (RE) (inverted repeat 2) of SSR recognition site.
g Heterotypic target sites of the φC31 SSR are included here for reference. Core nucleotide triplets (CAA) where the φC31-mediated
recombination occurs are underlined.
events into the ES cell genome, at least not when proper 1996). This set of Flp recombinase variants (Flp-wt, Flpe,
and Flp-L) collectively span an10-fold range in activitystrategies are applied (A. Nagy, personal communica-
tion). Of note, pseudo loxP sites have also been identi- in vivo (Dymecki, 1996; Dymecki and Tomasiewicz, 1998;
Rodriguez et al., 2000; Rodriguez and Dymecki, 2000;fied in the mouse genome (Thyagarajan et al., 2000),
although, given the widespread success of Cre to engi- Awatramani et al., 2003), and may be exploited, for ex-
ample, to achieve a range of cellular resolution in fateneer desired rearrangements in vitro and in vivo, these
sites do not appear to be an impediment. In cases where mapping studies (the application of SSRs for fate map-
ping is discussed further below).pseudo-loxP sites have been involved in unexpected
recombination events (resulting in cell growth arrest and With the goal of maximizing Cre activity, the cre gene
has been modified to be more eukaryotic-like (Shimshekchromosomal aberrations), Cre was expressed at very
high levels (Schmidt et al., 2000; Loonstra et al., 2001). et al., 2002). Changes include a reduced CpG content,
an improved Kozak translation initiation consensus se-To maximize further the utility of SSRs in mice, atten-
tion has also been directed at the recombinases them- quence, and a number of silent mutations reflective of
human codon-usage preferences. Indeed, the encodedselves. A number of groups have developed protein evo-
lution strategies to manipulate under various conditions iCre (for improved Cre) was detected at an 1.6-fold
higher concentration than conventional Cre when ex-the enzymatic properties of Cre and Flp to create new
recombinase variants (Buchholz and Stewart, 2001, and pressed from an identical vector; commensurate with
this increase in protein levels, iCre was found to beSantoro and Schultz, 2002, for Cre; and Buchholz et al.,
1998, and Voziyanov et al., 2003, for Flp). For example, 1.8-fold more efficient at DNA recombination than con-
ventional Cre.an error-prone PCR strategy has been used to develop
a Flp variant with increased thermostability (Buchholz Ligand-regulated forms of Cre and Flpe have also
been developed, with the goal of adding temporal con-et al., 1998). This enhanced form of Flp, called Flpe,
exhibits an 4-fold increase in recombinase activity trol to SSR activity so as to enable the induction of
genetic changes late in embryogenesis and/or in adultfrom wild-type when analyzed in cell culture. In mice,
Flpe readily mediates recombination between FRTs sep- tissues (as opposed to at the onset of recombinase
expression). One particularly successful strategy for in-arated by as little as a few kilobases (kb) (Farley et al.,
2000; Rodriguez et al., 2000; Awatramani et al., 2003) ducing SSR activity has involved fusing a mutant estro-
gen receptor (ER) ligand binding domain (LBD) to the Cor as much as 150 kb (F. Stewart, personal communica-
tion). A low-efficiency Flp, Flp-L, contains a single amino terminus of Flp (Logie and Stewart, 1995) or Cre (Metzger
et al., 1995; Feil et al., 1996; Kellendonk et al., 1996;acid substitution (F70L) resulting in an5-fold decrease
in recombinase activity from wild-type (Buchholz et al., Brocard et al., 1997; Schwenk et al., 1998) (Figure 5A).
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Figure 3. Use of Cre or Flp Spacer-Variant
Target Sites to Achieve Stable DNA Cassette
Exchange or Inversion
(A) Recombinase-mediated cassette ex-
change (RMCE). This insertion reaction ex-
ploits the fact that recombination is efficiently
mediated only between pairs of homotypic,
but not heterotypic target sites that vary in
their spacer sequence. A selectable marker
gene (SM) flanked by a pair of heterotypic
spacer-variant lox or FRT sites may be stably
replaced by a gene-of-interest (GOI) flanked
by similar sites. This reaction involves two
recombinase-mediated events: an integra-
tion step, followed by an excision step, leav-
ing heterotypic target sites (e.g., an FRT and
an F3 site) flanking the exchanged cassette
that may be used in additional rounds of
RMCE. In RMCE reactions, the heterotypic
target sites may be directly oriented or in-
verted with respect to one another; an advan-
tage of using inverted sites (as shown) is that
cassette excision is prevented should pro-
miscuous recombination be possible be-
tween heterotypic target sites.
(B) The FLEx switch. Stable DNA inversion
using the FLEx principle, applied here to in-
vert the orientation of gene X and gene Y.
Such a strategy could be employed to swap a
coding sequence downstream of a promoter/
enhancer element. The FLEx switch involves
two recombination events: an inversion step,
followed by an excision step. Following inver-
sion at either wild-type or mutant target sites,
pairs of homotypic sites flank a heterotypic
target site. Recombination between these di-
rectly oriented homotypic sites (separated by
at least 82 bp) results in the excision of the
heterotypic site, and the inverted cassette is
locked into place. Although not subject to
further inversion, the recombinant product,
flanked by heterotypic spacer-variant target
sites, could serve as a substrate for subse-
quent rounds of RMCE.
Currently, there are three different ERs available, all of discussed below.) Assays comparing the activity of
CreERT with CreERT2 indicate that CreERT2 is 10-foldwhich are insensitive to endogenous -estradiol, but
responsive to the synthetic estrogen antagonist 4-OH more sensitive than CreERT for both nuclear transloca-
tion and recombinase activity (Indra et al., 1999). Atamoxifen (4-OH-TAM): (1) mouse ERTM with a G525R
mutation (Danielian et al., 1998; Guo et al., 2002; Hayashi FlpeERT2 system has been developed recently; prelimi-
nary studies show inducible recombinase activity in vitroand McMahon, 2002; Zirlinger et al., 2002), (2) human
ERT with a G521R mutation (Logie and Stewart, 1995; and in vivo comparable to that observed with CreERs
(N. Lu, R. Awatramani, and S.M.D., unpublished data).Metzger et al., 1995; Feil et al., 1996; Brocard et al.,
1997; Schwenk et al., 1998; Li et al., 2000; Vooijs et al., This ligand-regulated “switch” for turning on recombi-
nase activity is now being exploited in two prototypal2001), and (3) human ERT2 containing three mutations
G400V/M543A/L544A (Feil et al., 1997; Indra et al., 1999; ways: (1) broad expression of recombinase::ER fusions
to enable temporal control of recombinase activity inKimmel et al., 2000; Imai et al., 2001; Seibler et al., 2003).
(Note that TAM, which is converted by the liver to the most tissues (Guo et al., 2002; Hayashi and McMahon,
2002; Seibler et al., 2003; and N. Lu, R. Awatramani,active inducer 4-OH-TAM, is often administered rather
than 4-OH-TAM because it is more soluble in solution and S.M.D., unpublished data); and (2) tissue-restricted
expression of these fusions using specific enhancer ele-and is less costly.) Using the broadly active CAG pro-
moter (chicken -actin promoter coupled with cytomeg- ments (Logie and Stewart, 1995; Danielian et al., 1998;
Schwenk et al., 1998; and N. Lu, R. Awatramani, andalovirus enhancer sequences) (Niwa et al., 1991) to drive
CreERTM expression in embryos, recombination was de- S.M.D., unpublished data)—these mice permit both tem-
poral and spatial control of recombinase activity. Whiletectable in many cell types by 15 hr post-TAM injection,
peaking by 48 hr (Hayashi and McMahon, 2002). (Meth- the doses, routes, and frequency of TAM or OH-TAM
administration are still being optimized, initial reportsods of detecting recombinase activity within cells are
Developmental Cell
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Figure 4. Use of Cre or Flp Inverted Repeat-Variant Target Sites to Achieve Stable DNA Insertion or Inversion
Stable DNA insertions (A) or inversions (B) may also be achieved exploiting lox or FRT sites that contain established substitutions in either
the left or right inverted repeat, also referred to as the left element (LE) or right element (RE), respectively. While two wild-type (wt) target
sites can recombine with each other repeatedly, an LE and RE mutant site will recombine efficiently only once, creating two different sites,
a wild-type and a doubly (LE & RE) mutant inert site, that cannot recombine efficiently with each other. SM, selectable marker; GOI, gene-
of-interest.
have uncovered interesting biology, including the timing report described use of the interferon-/ inducible pro-
moter of the Mx1 gene to drive cre expression in vivoof specification of sensory and autonomic neural crest
sublineages (Zirlinger et al., 2002). (Kuhn et al., 1995). The Mx1 gene, normally involved in
defense to viral infection, is silent in healthy mice, butThe fusion of a mutant progesterone receptor (PR)
LBD linked to the C terminus of Cre has also been ex- can be induced to high levels of expression upon appli-
cation of interferon- or -. While an important proof ofplored. For example, the fusion Cre-PR1 has been found
to be largely insensitive to endogenous progesterone, concept, use of this system has been limited by the
inability to induce recombination in certain cell types,but responsive to the synthetic steroid RU 486 (Kellen-
donk et al., 1996). For certain applications, Cre-PR1 has slow induction kinetics, and the cost of the inducing
agent.been effective in vivo, such as in adult epidermis to
model human skin disorders (Arin et al., 2001; Cao et A second transcriptional mechanism to achieve tem-
poral control of cre or Flp expression involves the tetra-al., 2001). Evidence suggests that it may be effective in
utero as well (Zhou et al., 2002). A drawback to Cre- cycline (tet) responsive system (Gossen and Bujard,
1992) (Figure 5B). This system involves two components:PR1, however, is the leakiness of this system, with some
degree of recombinase activity detectable even in the (1) a transactivator gene, encoding a fusion protein that
specifically binds tet (or the tet analog, doxycyclineabsence of inducer. An improved Cre-PR, however, has
been developed, termed Cre*PR, which confers lower [dox]) as well as operator sequences of the tet operon
(tetO), and (2) a tetO::recombinase transgene (St-Ongebackground activity and increased sensitivity to RU 486
(Wunderlich et al., 2001). Through application of both et al., 1996; Strathdee et al., 1999). The fusion protein
encoded by the transactivator gene is termed tTA andCre*PR and FlpeERT2, it should be possible to induce
two genetic events at unique time points in the same is composed of the E. coli tetracycline repressor fused
to the acidic domain of the herpes simplex viral proteinanimal. This capability offers tremendous potential to
the types of experiments possible with SSR technology. 16 (VP16) transactivation domain. In the absence of tet
(or dox), tTA binds tetO DNA to activate transcriptionAn alternative approach to temporally regulate SSR
activity is to regulate SSR transcription. The first such from a minimal promoter located immediately upstream
Review
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Figure 5. Mechanisms for Temporal Control of SSR Activity
(A) Posttranslational control of SSR activity. Recombinase-steroid fusion proteins are inactive in the absence of cognate steroid hormone due
to sequestration of the fusion protein into an Hsp90 complex. Binding of cognate steroid hormone to the recombinase-steroid fusion protein
results in disruption of the Hsp90 interaction, freeing the recombinase to enter the nucleus and mediate recombination at its target sites
(black triangles). As an example of this system, Flpe is shown fused to the ligand binding domain (LBD) of a mutant estrogen receptor.
Activation of the Flpe-ER fusion protein is achieved by administration of 4-hydroxy tamoxifen (4-OHT).
(B) Transcriptional control of SSR expression using the tTA tetracycline-responsive regulatory system. In the absence of the inducer in this
system, doxycycline (dox), the tTA (tetR-VP16) fusion protein is capable of binding to seven tandemly repeated 19 bp tetO sequences, resulting
in transcriptional activation of the recombinase and, in turn, SSR-mediated recombination at target sites. When bound to dox, tTA undergoes
a conformational change and cannot bind to tetO sequences.
(C) Transcriptional control of SSR expression using the reverse tTA (rtTA) tetracycline-responsive regulatory system. In the rtTA system, the
mutated rtetR-VP16 fusion protein is only capable of binding to tetO sequences in the presence of dox, resulting in transcriptional activation
of the recombinase and, in turn, SSR-mediated recombination at target sites. As an example in (B) and (C), cre expression is regulated by
the tTA and rtTA systems, respectively. TSP, tissue-specific promoter; TATA, representing a minimal promoter required for transcription; pA,
polyA signal sequence.
of the recombinase-encoding transgene. Thus, continu- rate of dox clearance, was reported to take from 24 hr
to a week, depending on the tissue examined (Kistnerous tet administration is required to prevent tTA binding
to tetO and for the suppression of recombinase expres- et al., 1996). Target silencing using tTA, on the other
hand, was achieved in embryos after 6 hr, and possiblysion. In order to induce recombinase expression, tet
administration is suspended, enabling tTA to bind to sooner as earlier time points were not examined (Shin
et al., 1999). Taking advantage of the kinetics achievedtetO. By contrast, a “reverse” tTA (termed rtTA) has been
engineered that only binds tetO in the presence of tet for gene activation and silencing using the rtTA and tTA
systems, respectively, it was determined that endothelin(Figure 5C). Using rtTA, recombinase expression is in-
duced by the administration of tet, thereby enabling rtTA receptor-B expression is required for a restricted period
of neural crest development, between embryonic daysto bind to tetO.
In addition to their converse mechanisms of tetO bind- 10 and 12.5 (Shin et al., 1999).
An important point to consider when using the teting, rtTA and tTA also differ significantly in their kinetics
of transcriptional activation. Using rtTA, transgene ex- system is that tight regulation of recombinase expres-
sion depends on the integration site of the tetO::recom-pression has been detected within 1 hr of dox adminis-
tration in adults (Hasan et al., 2001; Schonig et al., 2002) binase transgene. Indeed, a number of tetO::cre strains
have been generated that express cre in a manner thatand within 13 hr in embryos (Shin et al., 1999). By con-
trast, with tTA, target induction, which depends on the is neither dependent on nor affected by dox treatment
Developmental Cell
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(Leneuve et al., 2003), presumably due to neighboring modification). The second pitfall in traditional gene-tar-
geting strategies is the maintenance of the positive se-endogenous enhancers acting on the tetO-associated
lection cassette within the targeted gene. Its presenceminimal promoter. Importantly, a tetO::cre strain has
can cause a number of problems, such as the disruptionbeen described, termed LC-1, in which cre expression
of neighboring gene expression due to strong transcrip-is indeed tightly controlled in the absence of dox, but
tional regulatory elements frequently present in selec-efficiently induced following rtTA expression and dox
tion cassettes (Lerner et al., 1993; Ohno et al., 1994).administration (Schonig et al., 2002). Coupled with tis-
While removal of a positive selection cassette to avoidsue-restricted tTA or rtTA transgenes and loxP-flanked
the associated deleterious effects can be achieved withtarget sequences, the LC-1 locus should have broad
a second gene-targeting step leaving a “clean” mutationuse.
(using, for example, the “hit-and-run” [Askew et al.,Driven by experimental need, the sophistication and
1993] or “double-replacement” [Stacey et al., 1994; Wuversatility of SSR-based tools has grown tremendously
et al., 1994] approach), a relatively simpler strategy isover the last decade through the efforts of numerous
to use Cre or Flp either in vitro or in vivo to exciseinvestigators. Equally impressive has been the applica-
a selection cassette that has been either loxP-flankedtion of these tools to further our understanding of devel-
(“floxed”) or FRT-flanked (“flrted”), respectively.opment and disease.
The first report of conditional gene modification exam-
ined the effect in T cells of a null mutation in the essential
DNA polymerase  (pol) gene (Gu et al., 1994). In thisReverse Genetics Takes a Big Step Forward:
type of experiment, a mouse line is constructed thatPartnering Homologous Recombination with
carries two components: (1) a recombinase transgeneSSRs to Achieve Conditional Gene (In)Activation
for the expression of Cre or Flpe in a restricted domain,Gene-targeting in ES cells and the production of knock-
and (2) a target gene in which a given segment hasout (KO) mutant mice substantiated the utility of the
been either floxed or flrted, respectively (note that micemouse as a genetic model system for elucidating mam-
should be either homozygous or heterozygous over amalian gene function (Kuehn et al., 1987; Thomas and
null allele for the floxed or flrted locus). In mice, theCapecchi, 1987, 1990; Koller and Smithies, 1989; McMa-
targeted gene segment will be deleted specifically inhon and Bradley, 1990). Fundamental to these achieve-
cells expressing the recombinase and their descen-ments were the successful isolation and culture of mouse
dants, while the target gene will remain intact in otherES cells (Evans and Kaufman, 1981; Martin, 1981), the
cells of the mouse, where the recombinase is not ex-demonstration that they could be used to recolonize the
pressed. This binary design offers great versatility togermline (Bradley et al., 1984), even following genetic
gene function studies: the role of one gene may bemanipulation (Gossler et al., 1986; Robertson et al.,
assessed in a variety of lineages, by crossing different1986), and the development of gene-targeting, the intro-
recombinase lines (with differing recombinase expres-duction of DNA sequences into a chromosome by ho-
sion patterns) to one strain bearing a conditional allelemologous recombination (Smithies et al., 1985; Thomas
of a single gene; alternatively, the function of differentand Capecchi, 1986).
genes may be assessed in a single lineage, by crossingToward creating a KO mouse, the traditional gene-
one recombinase line to multiple strains each carryingtargeting strategy is to replace the target gene, or at
a conditional allele of a different gene.least an essential part of the gene (up to 20 kilobases
Regarding the second pitfall of traditional gene-tar-[kb] [Zou et al., 1994]), with a positive selection marker,
geting, removal of a floxed or flrted positive selectionusually the neomycin phosphotransferase gene (neo),
cassette can be achieved either in vitro or in vivo, withpermitting isolation of recombinant ES cells in culture.
advantages inherent to both strategies. A benefit of re-A standard replacement vector contains the positive
moving the positive selection marker in ES cells is that
selection marker flanked by genomic DNA homologous
the second allele can be subsequently modified with the
to the target, with a negative selection gene, usually the
same targeting vector to create ES cells homozygous for
HSV-tk or diphtheria toxin A subunit (DTA) gene, on one the desired alteration. Removal of a floxed cassette in
end. The negative selection marker simply enriches for cell culture has been aided by the fusion of Cre to a basic
the desired homologous recombination event over ran- peptide from HIV-TAT, which has been demonstrated to
dom integrations by killing cells that have retained the promote the cellular uptake of Cre (Peitz et al., 2002),
negative selection gene. eliminating the need to electroporate recombinant ES
Although a powerful approach, this traditional method cells with a Cre-encoding plasmid. By contrast, a benefit
of gene-targeting has two potential pitfalls that have of removing the positive selection cassette in vivo is the
been resolved with SSR technology. The first and major opportunity to create an allelic series for a given gene,
pitfall is that many genes serve an essential function, by taking advantage of the fact that the presence of the
and so the elimination of gene activity throughout the neor cassette often partially disrupts gene expression.
entire animal can result either in early embryonic lethal- In this case, removal of the selection cassette can be
ity, precluding the analysis of gene function at later achieved by crossing mice carrying the targeted allele
stages, or, alternatively, a masking of the full mutant to a “deleter” strain, a transgenic strain that expresses
phenotype due to genetic compensatory mechanisms. the relevant recombinase either early in embryonic de-
In these cases, site-specific recombination may be used velopment, or in the developing germline (Lewandoski
to inactivate a gene in discrete cells and/or at discrete et al., 1997, O’Gorman et al., 1997, and Leneuve et al.,
times during development within the context of an other- 2003 for Cre, and Rodriguez et al., 2000, and Farley et
al., 2000, for Flpe).wise normal mouse (a method termed conditional gene
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Figure 6. Strategies for Removing the Selection Cassette from a Conditional Allele
The thick line represents sequences within a targeting replacement vector homologous to a target locus in ES cells.  represents a positive
selection marker (such as neor ) and , a negative selection marker (such as HSVtk). Both positive and negative selection marker genes
contain a promoter and polyA sequences. The gray Xs represent homologous recombination crossover points. Positive and negative selection
are applied to select for the desired gene replacement event.
(A) A dual-recombinase strategy for selection marker removal. Following gene replacement with the targeting vector, a flrted positive selection
cassette is excised by Flpe. The reciprocal target site arrangement can be used to generate a flrted allele for conditional mutagenesis, with
loxP sites flanking the positive selection cassette.
(B) A tri-lox strategy for selection marker removal. Here, following gene replacement with the targeting vector, the floxed positive selection
cassette may be excised by transient expression of Cre, leaving the floxed exon in place (type II excision). Cre recombination may also result
in a null allele (type I excision) or excision of the floxed exon, leaving a floxed selection marker in place (type III excision).
The availability of two highly efficient site-specific re- were generated in a single gene-targeting experiment
using SSR technology. Most notably, by crossing micecombinase systems (Cre-loxP and Flpe-FRT) provides
a convenient means to create a conditional allele while harboring the reversion-to-wild-type allele (i.e., the
cleaned-up floxed allele) to a strain that expresses Cremaintaining the potential to remove the positive selec-
tion cassette from the gene-targeting construct (Figure in early limb ectoderm, it was determined that Fgf8 is
absolutely required for multiple aspects of normal limb6A). Such a dual-recombinase strategy was used to cre-
ate an allelic series for Fgf8: two essential exons of Fgf8 development (Lewandoski et al., 2000).
An alternative strategy to create a conditional allele(exons 2 and 3) were floxed, and a flrted neor cassette
placed in an intron just upstream of the 5 loxP site in which the positive selection cassette may be removed
is to position three loxP sites such that the selection(Meyers et al., 1998). Mice homozygous for this targeted
allele displayed perturbed brain development, consis- cassette is flanked as is the gene segment to be condi-
tionally deleted (a “tri-lox” approach) (Gu et al., 1993)tent with a hypomorphic phenotype for Fgf8; this mutant
phenotype was due to the presence of the neor cassette, (Figure 6B). A major caveat of this strategy, however,
has been the difficulty in obtaining a partially deletedas its removal by crossing to Flp deleter mice (Dymecki,
1996) resulted in reversion to a wild-type phenotype. allele in which the gene segment remains floxed but the
positive selection cassette has been removed (KaartinenPositioning the neor cassette within the first intron ap-
parently disrupted Fgf8 mRNA splicing, effectively re- and Nagy, 2001). However, using a new Cre recombi-
nase mouse termed MeuCre40 (Leneuve et al., 2003),ducing mature Fgf8 transcripts and protein. By contrast,
crossing to a Cre deleter strain, creating a null allele in the desired partial deletion can be generated with rela-
tive ease. MeuCre40 is one of several tetO::cre strainsnearly all cells of the early embryo, produced an embry-
onic lethal phenotype, demonstrating an essential role found to produce mosaic, early embryonic, ubiquitous
(Meu) Cre expression neither dependent on nor affectedfor Fgf8 in gastrulation. Thus, three alleles, including
a null, hypomorphic, and reversion-to-wild-type allele, by dox treatment (Leneuve et al., 2003), presumably
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due to positional effects associated with the tetO::cre the resultant embryos being completely ES cell derived
chromosomal integration site. Upon intercrossing Meu- (Nagy et al., 1990, 1993; Seibler et al., 2003). Diploid F1
Cre40- and tri-lox allele-carrying mice, it is estimated hybrid ES cells (C57Bl/6 X 129S4Sv/Jae) generate live
that approximately two F2 litters (30 F2 mice) need to pups with high efficiency, by contrast to most diploid
be screened in order to isolate one animal carrying a inbred ES cells (Eggan et al., 2001).
deletion specifically of the selection cassette. An advan-
tage of using the Cre-loxP system both to create a condi- Recombineering BACs to Generate
tional allele and to remove the positive selection cas- Conditional Gene-Targeting Vectors
sette is that it permits application of the Flpe-FRT and Recombinase Transgenes
system to achieve other conditional manipulations in An important consideration for conditional gene modifi-
the animal. cation experiments is the time required for vector con-
Conditional gene modification provides the potential struction, be it a gene-targeting vector or a recombinase
for careful analysis of gene inactivation in specific cell transgene. This process has been expedited through
lineages. In many cases, however, gene inactivation is development of “recombineering” strategies that exploit
not complete due to a failure of the recombinase to E. coli homologous recombination systems to modify
modify the target gene in all cells expressing the recom- introduced exogenous DNA. Indeed, recombineering
binase. Such mosaicism of recombinase-mediated exci- represents a flexible and efficient means with which to
sion precludes an analysis of a null phenotype in the construct insertions, deletions, and point mutations in
target lineage, due to the existence of wild-type cells a given DNA sequence without any other residual
that may mask a potential defect. In fact, this issue changes in the recombinant product and without the
confounded the analysis of pol in T cell lineages in need for suitable restriction enzyme recognition sites.
the first conditional KO experiment (Gu et al., 1994). To For the production of gene-targeting vectors and re-
overcome this caveat, it is possible to use conditional porter constructs, recombineering strategies have been
gene modification to achieve lineage-specific gene re- applied most commonly to bacterial artificial chromo-
pair in an otherwise null background. This method could somes (BACs). This is because (1) BACs are readily
also be used to determine where in the animal a gene available for most genes having represented the primary
is required for viability. source of archived DNA for the mouse genome sequenc-
By combining a gene-targeting strategy with a re- ing project; (2) BACs can be used directly in ES cells
porter for recombinase activity, it is also possible to for high-fidelity gene replacement (Liu et al., 2003; Valen-
mark cells directly that have undergone Cre-dependent zuela et al., 2003; Yang and Seed, 2003); and (3) for
gene inactivation, enabling the precise distinction of most genes, BACs can be identified that contain all
mutant versus wild-type cells in the target gene expres- necessary regulatory elements to confer normal gene
sion domain (Theis et al., 2001; Schnutgen et al., 2003). expression (Heintz, 2001). Moreover, BAC transgenes
For example, the FLEx switch (Schnutgen et al., 2003) are not subject typically to the strong position effects
(described above) was used to activate -galactosidase resulting in transgene silencing or misexpression that
(-gal) activity in cells in which the retinoic acid receptor
plague conventional constructs (20 kb). It is important
	 (RAR	) gene had been inactivated by Cre. LacZ in this
to note that BAC vector sequences contain loxP sites.
case is expressed under the regulatory control of the
If left in the mouse genome, as is often the case when
target RAR	 gene and is therefore expressed in mutant
generating a BAC transgenic by zygote injection (butcells only within the window of time that RAR	 is nor-
not by homologous recombination), these sites may par-mally expressed; notably, it does not serve as a lineage
ticipate in undesired recombination events, complicat-tracer (application of SSRs for tracing cell lineages is
ing use of Cre-loxP technology in these animals. Thesediscussed below). The FLEx switch strategy of replacing
unwanted sites may be removed using additional recom-one open reading frame with another using site-specific
bineering strategies (Yang et al., 1997; Lee et al., 2001;recombination could be applied for a number of applica-
Gong et al., 2002) or by isolating the BAC insert awaytions, such as conditional rescue of a gene KO, con-
from vector sequences.ditional point mutations, and conditional gene re-
In general, the large size of BACs requires their main-placement.
tenance and propagation in a homologous recombina-While essential for functional analyses, conditional
tion-deficient strain of E. coli (DH10B) to prevent theirgene modification strategies are encumbered by the
rearrangement (Shizuya et al., 1992). Recombineeringtime required to generate mice that are homozygous for
strategies involve the restoration of homologous recom-the floxed or flrted allele and carry the recombinase
bination potential to bacteria for a brief window of timetransgene—three breeding steps, requiring up to 14
concurrent with the introduction of DNA sequences tomonths. An alternative approach requiring less than half
be inserted into or exchanged with the BAC. Ideally, thethis amount of time as well as far fewer animals is to
window of homologous recombination potential is justgenerate ES cells harboring the desired genotype and
wide enough to permit the desired alteration, followingto then generate mice derived entirely from these cells.
which the E. coli return to a recombination-deficientUse of F1 hybrid ES cells permits the necessary consec-
state suitable for maintenance of the modified BAC. Theutive rounds of gene-targeting while maintaining ES cell
first reported recombineering methodology involvedtotipotency; use of tetraploid blastocyst complementa-
restoration of the RecA homologous recombinationtion methods enable the production of entirely ES cell-
pathway (Yang et al., 1997), followed soon after by usederived mice. Tetraploid blastocysts are develop-
of the RecE/RecT pathway for this purpose (Zhang etmentally compromised, but when complemented by
diploid ES cells will complete fetal development with al., 1998). Notably, both strategies have been used in
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high-throughput BAC modification projects for the pro- strategies deliver high ratios of correct (homologous) to
duction of transgenic mice: RecA-mediated recombi- incorrect (illegitimate) recombinations.
neering (Gong et al., 2002) has been used for the inser- The homology arms required for ET/Red recombina-
tion of reporter sequences into hundreds of BACs with tion are short. Consequently, they can be generated by
the aim of reporting gene expression patterns in the oligonucleotide synthesis, which can be attached to a
brain and of gaining genetic access to every cell type selectable marker by PCR amplification. FRT or loxP
in the CNS (as part of the GENSAT BAC Transgenic sites can also be included in the synthetic oligonucleo-
Project [http://www.gensat.org/index.html]) (Gong et al., tides, and hence the PCR product that is then recom-
2003), and a modified RecE/RecT-based strategy has bined into the mouse genomic DNA clone. These experi-
been applied in VelociGene, a high-throughput and mental simplicities permit (1) the rapid, one step,
largely automated method for the genetic modification construction of targeting constructs for homologous re-
of endogenous genes, applied recently to generate re- combination in ES cells (Angrand et al., 1999; Lee et al.,
porter expression patterns for hundreds of genes in mice 2001; Muyrers et al., 2000; Zhang et al., 2002; Yang and
(Valenzuela et al., 2003). Using the gene expression data Seed, 2003; Valenzuela et al., 2003; Liu et al., 2003), and
derived from these projects, BAC::recombinase trans- (2) rapid insertion of loxP or FRT sites into any chosen
genics can be generated to achieve SSR activity in spe- position in targeting constructs or BAC transgenes
cific cell populations in vivo. (Zhang et al., 1998, 2000; Angrand et al., 1999; Liu et
The RecA strategy (Yang et al., 1997; Gong et al., 2002) al., 2003; Testa et al., 2003). This cloning strategy greatly
involves the introduction of a single plasmid, referred to facilitates the introduction of site-specific recombinase
as a “shuttle vector,” into the BAC E. coli host. Contained target sites into the mouse genome, which has been
within the shuttle vector are RecA and DNA sequences a limiting step for the application of SSR technology.
to be incorporated into the BAC, such as a reporter or Through further implementation of recombineering, it is
recombinase gene, flanked by 500 bp homology arms now possible to simultaneously alter two or more sites
corresponding to sequences in the BAC. The desired separated by distances up to the cloning capacity of
modification of the BAC is achieved in two consecutive BACs (250 kb). For example, Red recombination has
homologous recombination steps, termed “cointegra-
been employed to produce gene-targeting constructs
tion” and “resolution” (mechanistically similar to the
to create conditional alleles in which recombinase target
RMCE reaction, depicted in Figure 3A). Cointegration
sites are positioned at significant distances from each
describes the insertion of the entire shuttle vector into
other (Liu et al., 2003; Testa et al., 2003). More specifi-the BAC by homologous recombination between the
cally, a 64 kb targeting construct was used to direct thehomology arms of the vector and the BAC, while un-
simultaneous insertion of two cassettes, one flanked bywanted BAC vector sequences are then “resolved,” or
FRT, and the other by loxP, sites into the Mll gene ineliminated, through a second homologous recombina-
ES cells. The dually modified Mll allele has four possibletion event. In the course of modifying an initial set of
configurations depending upon recombination or not byBACs, average efficiencies of 75% for cointegration and
Flp, Cre, or both, thus permitting the production of three63% for resolution were reported (Gong et al., 2002).
Mll alleles in vivo including a null allele, a truncationThe alternative method of BAC modification involves
allele typically observed in Mll-associated childhoodregulated expression of phage homologous recombina-
leukemia, and a reversion-to-wild-type allele (Testa ettion proteins in BAC host cells: either RecE/RecT from
al., 2003).Rac prophage (Zhang et al., 1998) or Red/Red from
the Red operon of lambda phage (Muyrers et al., 1999;
Yu et al., 2003). Thus, this method is referred to as either
Trap and Release: A New Generation of Gene-“ET” or “Red” recombination. Upon expression of the
Trap Vectors Enable Postinsertional Modificationsphage proteins in a BAC host, a linear double-stranded
A significant step toward functionally annotating the hu-DNA fragment, flanked by relatively short homology
man genome will be the determination of loss-of-func-arms (50 bp), will be homologously recombined into the
tion phenotypes for every gene in the mouse. As anidentical sequences in the BAC at high efficiency. This
alternative approach to systematically knocking outmethod was devised following an observation that ho-
genes by gene-targeting, a number of groups havemologous recombination between linear and circular
launched large-scale, random mutagenesis screens us-DNA molecules can be achieved in sbcA strains in which
ing either gene-trap vectors in ES cells (Hansen et al.,RecE and RecT are expressed (due to the sbcA mutation
2003; Stryke et al., 2003) or the chemical agent N-ethyl-that activates expression of an integrated prophage en-
N-nitrosourea (ENU) in vivo (Hrabe de Angelis et al.,coding the recE/recT operon [Clark, 1973; Lloyd, 1974;
2000; Nolan et al., 2000; Coghill et al., 2002; Herron etWinans et al., 1985]). The method was then developed
al., 2002). Both strategies make no a priori assumptionsusing the analogous red operon from lambda phage.
regarding gene function but differ in the types of muta-To enable ET/Red recombination in any recombination-
tions produced. A standard gene-trap vector containsdeficient E. coli cell line, several ways to regulate the
a promotorless reporter gene flanked by an upstreamexpression of RecE and RecT, or Red and Red, have
splice acceptor and a downstream polyadenylation (po-been developed. These usually include coexpression
lyA) signal sequence (Gossler et al., 1989). When in-of Red	, which inhibits the major E. coli exonuclease,
serted into an intron, transcriptional activation of theRecBCD, preventing degradation of linear DNA frag-
“trapped” gene will result in a fusion transcript com-ments (Elledge and Walker, 1985; Murphy, 1998; Poteete
et al., 1999). Notably, both RecA and ET/Red cloning posed of upstream coding sequences and the reporter.
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(-geo, a -gal-Neo fusion, tolerates N-terminal exten- SSR systems (H. von Melchner, personal communica-
tion). The result of this clever design is that a gene-trap-sions and so is well suited for this purpose.) This gene-
induced mutation may be repaired in ES cells, facilitatingtrap design generally produces a null allele while simul-
passage of the modified locus through the germline intaneously revealing the expression of the endogenous
the production of transgenic mice, followed by the re-gene. Variations in the design of gene-trap vectors have
generation of the gene-trap-induced mutation in a con-increased the efficiency and selectivity of gene trapping
ditional manner in vivo.in ES cells (Stanford et al., 2001). Building on the basic
vector design described above, some gene-trap vectors
not only contain a promotorless reporter gene, but also Chromosomal Engineering with the Cre-loxP
System to Model Human Diseaseinclude either a start ATG or an internal ribosomal entry
Chromosomal rearrangements are a major cause of in-site (IRES), and, as such, are able to trap both the coding
herited human disease and fetal loss, and have beenand the 5 untranslated region (5 UTR) of genes, with
associated with the progression and maintenance ofthe potential to mutate specific isoforms as well as to
cancer (Ramirez-Solis et al., 1995; Rabbitts et al., 2001).produce null alleles. Still other gene-trap vectors permit
For example, a number of the contiguous gene syn-the identification of particular classes of genes, such as
dromes, associated with disruptions in gene dosage,those that are transiently or actively transcribed (Thorey
such as Smith-Magenis and DiGeorge, have been attrib-et al., 1998), that are induced following steroid hormone
uted to specific chromosomal rearrangements (Walz etstimulation (Wan and Nordeen, 2002), or that encode
al., 2003). In addition, many cancers are associated withsecreted or transmembrane proteins (Skarnes et al.,
specific translocations, such as the coincidence of B1995; Mitchell et al., 2001). By contrast, ENU alkylates
lymphoid cell tumors with the translocation t(4;11), af-DNA to produce point mutations or small deletions, the
fecting the MLL and AF-4 genes (Rabbitts et al., 2001).majority of isolated alleles predicted to be missense
Chromosomal translocations often result in abnormalmutations (Justice et al., 1999). As a result, ENU-derived
gene fusions and, consequently, tumor-specific mRNAsalleles can reveal critical amino acids for protein func-
and proteins that represent attractive targets for ther-tion, complementing loss-of-function gene studies.
apy. Thus, a capacity to engineer chromosomal re-ENU-derived mutations must be mapped to determine
arrangements with specific breakpoints is critical to ourthe affected gene and then molecularly characterized.
ability to model human disease in the mouse, and couldBy contrast, gene-trapping offers a comparatively quick
facilitate the development of disease therapies.means of gene identification by 5 rapid amplification
Four groups independently pioneered use of the Cre-of cDNA ends (RACE), for which the fusion transcript
loxP system for chromosome engineering to generateserves as template. Alternatively, some gene-trap vec-
either a specific translocation (Smith et al., 1995; Vantors permit gene identification by plasmid rescue (Araki
Deursen et al., 1995), a large deletion (Li et al., 1996), oret al., 1999). Currently, BayGenomics (Stryke et al., 2003)
a set of deletions, duplications, and inversions (Ramirez-(http://baygenomics.ucsf.edu) and the German Gene
Solis et al., 1995). Which of these modifications is gener-
Trap Consortium (Hansen et al., 2003) (http://genetrap.de)
ated depends on the relative orientation of loxP sites
are the largest libraries of gene-trap ES cell lines avail-
positioned within the genome. If two loxP sites are posi-
able to the public. Combined, these resources contain
tioned in the same orientation on a single chromosome
insertions in 14% of genes currently annotated in or homologous chromosomes, then a deletion and/or
Ensembl (http://ensembl.org) (W. Skarnes and H. von duplication can be made. If instead, two loxP sites are
Melchner, personal communication). positioned in the opposite orientation, an inversion can
To increase the versatility of the gene-trap approach, be isolated; dicentric and acentric chromosomes may
several groups have modified gene-trap vectors to in- also be produced in this case but cause cell lethality.
clude wild-type and variant SSR recognition sites en- Finally, if two loxP sites are positioned on different chro-
abling postinsertional modifications of the trapped gene mosomes, a balanced translocation can be generated
(Araki et al., 1999; Hardouin and Nagy, 2000). Postinser- by mutual exchange of DNA distal to the loxP sites.
tional modification could involve SSR-mediated man- Using the publicly available mouse genome sequence,
ipulation of the integrated vector to achieve an allelic the relative orientation of genes with respect to each
series of the trapped gene (for example, a null, hypomor- other and the centromere can be determined with few
phic, reversion-to-wild-type, and neomorphic allele), or, exceptions, enabling the correct orientation of loxP sites
alternatively, to achieve ectopic expression of another in the ES cell genome depending on the rearrangement
gene under the regulatory control of the trapped cis- desired. This also abrogates the need to target loxP
acting promoter or enhancer elements. Notably, FRT sites in both directions within target genes. Following
and heterotypic lox sites have been incorporated into the sequential targeting of two loxP sites into the ES
the vectors used to generate most of the ES cells lines cell genome, Cre-mediated recombination to produce
in the BayGenomics resource, enabling the application the rearrangement may be achieved either in vitro or
of Cre-lox and Flp-FRT technology to transform gene- in vivo.
trap events into virtually any desired allele (W. Skarnes, For the generation of substantial genomic re-
personal communication). Furthermore, a FLEx switch arrangements involving the placement of loxP sites on
strategy (see Figure 3B) has been applied in a new gen- different chromosomes or on the same chromosome
eration of gene-trap vectors, permitting these vectors but at distances exceeding ten megabases (Mb) (Mills
to be inverted twice following their insertion into the ES and Bradley, 2001, and discussed below), the efficiency
of Cre recombination is low enough that a selectioncell genome by the successive activation of two different
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system for the desired rearrangement is recommended. while the efficiency of Cre-mediated recombination de-
To address this need, two groups independently devel- creases with increasing genetic distance between loxP
oped strategies in which a positive selection marker is sites on the same chromosome (in cis), it does not ap-
reconstituted following the Cre-mediated genomic alter- pear to be limiting, with the extent of the rearrangement
ation (Ramirez-Solis et al., 1995; Smith et al., 1995). For that can be made apparently more a function of ES cell
example, Cre-mediated recombination between loxP viability than a limitation of the Cre-loxP system. By
sites has been used to juxtapose the 5 and 3 halves contrast, the efficiency by which Cre mediates recombi-
of an Hprt gene, thereby reconstituting this selectable nation in trans is fairly low, in the range of in 103 (Van
marker and rendering ES cells bearing this rearrange- Deursen et al., 1995) to 105 (Smith et al., 1995; Zheng
ment resistant to hypoxanthine, aminopterin, and thymi- et al., 2000), and may reflect chromosomal position
dine (HAT) (Ramirez-Solis et al., 1995). (Note that when within the cell during interphase and mitotic metaphase
using this type of selection, the ES cells must be initially (Testa and Stewart, 2000).
Hprt deficient.) An advantage of constructing large-scale chromo-
To aid in the production of chromosomal rearrange- somal rearrangements in vitro is the option of using a
ments using this selection system, two different genomic positive selection system to facilitate isolation of the
libraries of pre-made gene-targeting insertion vectors rearrangement. In certain cases, however, it must be
have been made. They are referred to as the 5 Hprt accomplished in vivo. This is achieved by generating
and 3 Hprt libraries (Zheng et al., 1999). The vector mice with appropriately positioned loxP sites, followed
used to create the 5 Hprt library contains the 5 Hprt by restricted cre expression within the animal, thereby
cassette (containing the 5 half of the Hprt gene which producing the desired rearrangement within a small
itself is nonfunctional) with an embedded loxP site, the number of cells, much like a conditional gene-targeting
PGKneopbA (neo) gene as a positive selection marker, experiment. An in vivo approach may be required due
and the Tyrosinase (Ty) minigene. The vector used to to ES cell haploinsufficiency or infertility associated
create the complementary 3 Hprt library contains the with the transmission of translocations through the
3 Hprt cassette (containing the 3 half of the Hprt gene germline, or might be preferred in order to better model
which itself is nonfunctional) with an embedded loxP cancers that arise in somatic lineages due to a loss
site, the PGKpuropbA (puro) gene as a positive selection of heterozygosity. For example, translocations corre-
marker, and the K-14 Agouti (Ag) minigene. The vectors sponding to the human rearrangements t(8;21)(q22;q22)
were designed such that following recombination at loxP and t(9;11)(p22;q23) have been induced successfully in
sites, the reconstituted Hprt gene is flanked by the Ty the mouse (Buchholz et al., 2000, and Collins et al.,
and Ag coat-color markers, enabling the visible identifi- 2000, respectively) in order to model acute leukemias.
cation of mice carrying the rearrangement. In addition, In addition, in vivo chromosomal engineering may be
the neo and puro genes were designed to segregate used for the production of genetic mosaics, defined as
away from the reconstituted Hprt minigene in a charac- individuals that are heterozygous for a particular muta-
teristic fashion depending on the rearrangement made, tion but that contain patches of homozygous mutant
enabling the identification of ES cell clones bearing the cells (not to be confused with chimeras, defined as indi-
desired chromosomal rearrangement by sib selection. viduals derived from cells from different sources) (Liu
Sib selection is performed by duplicate plating individual et al., 2002). Genetic mosaics enable an assessment of
clones in order to assess their viability in the presence the requirement of gene function on clonal cell lineages,
of various drug combinations (HAT, G418, puromycin) and can be extremely informative in studying cell fate
(Yu and Bradley, 2001), and is particularly useful given determination and imprinting. Genetic mosaics are gen-
the range of recombination products that can occur, erated when mitotic recombination occurs after DNA
depending, for example, on whether loxP sites are local- synthesis in the cell cycle (in G2) and the recombinant
ized to one chromosome (recombination occurs in cis)
chromatids segregate to different daughter cells (re-
or homologous chromosomes (recombination occurs in
ferred to as X segregation), as opposed to the same
trans), as well as on when during the cell cycle recombi-
daughter cells (referred to as Z segregation) (Liu et al.,nation occurs, that is, in either G1 or in G2 following
2002). In Drosophila, the Flp-FRT site-specific recombi-DNA synthesis (see Supplemental Figure S2 at http://
nation system has facilitated the production of geneticwww/developmentalcell.com/cgi/content/full/6/1/
mosaics, yet because Drosophila chromosomes are7/DC1).
unique in that homologs align during mitosis (Metz,To assess the efficiency of Cre-mediated recombina-
1916), it was unclear if genetic mosaics could be identi-tion as loxP sites become separated by increasing dis-
fied among mice. However, Cre-loxP site-specific re-tance, a study was performed in ES cells in which the
combination has been used successfully to induce mi-frequency of isolating Cre-mediated inversions was de-
totic recombination with X segregation in ES cells, withtermined (Zheng et al., 2000). The focus was on mouse
a frequency of 7.0 
 103 to 4.2 
 105 depending onchromosome 11 as it is extensively conserved with hu-
genomic location (Liu et al., 2002).man chromosome 17 and contains several potential tu-
mor suppressor genes (Zheng et al., 2001). Inversions,
Mouse Forward Genetics on the Fly Usingas opposed to deletions, were analyzed in order to by-
SSR Technologypass any confounding issues of haploinsufficiency. As
Using chromosome engineering, an arsenal of reagentspredicted, HAT-resistant colonies were isolated at de-
previously limited to Drosophila is being assembled forcreasing frequencies as the distance between loxP sites
the mouse, including marked deletions, duplications,increased. In addition, recombination in cis occurred
roughly 200 times more frequently than in trans. Thus and inversions that collectively span the genome. These
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reagents will greatly increase the efficiency and flexibil- intercrossing with the appropriate deleter strain, re-
sulting in a chromosome tagged at the same geneticity of genetic screens and mapping studies conducted
in mice (for example, see Kile et al., 2003). Deletions, location with either eCFP or eYFP. Two key attributes
of this marker system are (1) that they may be used tooften referred to as deficiencies, render a segment of
the genome haploid and so can be used in focused F1 identify individuals carrying a marked chromosome at
any developmental stage, including embryos, unlikeor F2 screens for recessive mutations. Deletions are
also useful for mapping studies if their endpoints are coat-color markers that are restricted to postnatal ani-
mals, and (2) that they may be used to dominantly mark,known, and those generated with the Cre-loxP system
have the advantage that their endpoints are predeter- in theory, any position within the genome with either of
two fluorescent tags, and thus could be used to facilitatemined at the nucleotide level, unlike those produced by
ionizing radiation, for example. Cre-loxP site-specific targeted genetic screens at any region within the ge-
nome. To assess the utility of the transgene CX-YNC, itrecombination has also enabled the construction of
nested deletions series (Su et al., 2000), useful for map- was randomly inserted into ES cells and the insertion
sites mapped by plasmid rescue. ES cells in which theping recessive mutations to progressively smaller inter-
vals. Such deletions have been isolated by embedding transgene had integrated as a single copy were readily
isolated and found to strongly and uniformly expressthe first of two loxP sites at a fixed position in the genome
by conventional gene-targeting, followed by random in- both markers. One ES cell line was used to generate
mice in which dual color fluorescence was easily visual-tegration of the second site using a recombinant retrovi-
rus. Deletions and their complementary duplications, ized throughout development, including in pre- and
postimplantation embryos, newborn pups, and adultattainable using the Cre-loxP system, are extremely use-
ful for classifying uncharacterized mutations, such as mice. Widespread cyan and yellow fluorescence was
observed in all organs and tissues examined, includingthose isolated in ENU mutagenesis screens. For exam-
ple, a mutation can be classified as a bona fide loss- the brain, heart, lung, skin, and skeletal muscles. This
transgene could be homozygosed with no effect on via-of-function allele if (1) it fails to complement an overlying
deletion for a given mutant phenotype and (2) if the bility or fertility. Ideally, a bank of ES cells will be gener-
ated harboring the CX-YNC dual reporter in locationsphenotype associated with the homozygosed mutation
is rescued by an overlying duplication. Finally, Cre-loxP throughout the genome. Figure 7 depicts use of these
markers to distinguish the classes of progeny in F1, F2,site-specific recombination has permitted the genera-
tion of balancer chromosomes, which are dominantly or F3 focused screens: for recessive mutations in vivo
accompanying a deletion (Figure 7A), in ES cells accom-marked inversions rendered recessive lethal by placing
at least one of the endpoints within an essential gene. panying a deletion (Figure 7B), or in vivo accompanying
a balancer chromosome (Figure 7C). Importantly, theseBalancers are used to maintain recessive lethal muta-
tions and the integrity of mutagenized chromosomes markers can also be used to flag a missing class of
offspring due to the generation of a recessive lethalby suppressing meiotic crossovers within the inverted
region (Zheng et al., 2001). They can also be instrumental allele, and provide a mechanism for its recovery by facili-
tating the identification of carriers.to the isolation of ENU-induced recessive mutations
(Kile et al., 2003, and discussed further below). Each
balancer chromosome can span about one-third of a Molecular Fate Mapping in the Mouse: Switching
chromosome without issues of haploinsufficiency that on Lineage Tracers Using SSRs
plague large deletions. An effort to make a genome- Analyses of cell fate greatly inform our understanding
wide balancer series using SSRs is currently underway of normal development and provide an important frame-
at the Sanger Center (UK), each balancer tagged with work for analyzing genotype-phenotype relationships
dominant coat-color markers (Nishijima et al., 2003, and uncovered by mutagenesis. With rare exception (Tam
A. Bradley, personal communication). and Beddington, 1987; Turner and Cepko, 1987; Lawson
To increase the efficiency and flexibility of genetic and Pedersen, 1992; Walsh and Cepko, 1992), verte-
screens using deletions and balancer chromosomes, a brate fate maps have been plotted in avian and amphib-
system using SSRs has been developed that permits ian systems because of the ease of manipulating tissue
generating two distinct dominant fluorescent markers in ovo. Employed methods include the injection of ret-
at any location within the genome (Frank et al., 2003). roviral (Galileo et al., 1990; Cepko et al., 1993), fluores-
Dominant visible markers, such as those described here, cent (Wetts and Fraser, 1991), or vital dye lineage tracers
are extremely useful for genetic analysis because they (Keller, 1975, 1976), or the grafting of quail cells into
enable a chromosome to be followed without selection chick embryos (Le Douarin, 1982). Because mouse em-
or genotyping, and, used in conjunction with an overly- bryos develop in utero, they are less accessible, making
ing deletion or balancer chromosome, can be used to these established tracing methods more difficult. To
distinguish all classes of progeny in genetic screens. In circumvent this obstacle, SSR-based strategies have
this case, a plasmid, pCX-YNC, was devised that drives been developed to genetically (and noninvasively) acti-
broad expression of two different color variants of en- vate lineage tracers in mice.
hanced green fluorescent protein (eGFP), eCFP (cyan), Initial reports of SSR-based fate mapping included
and eYFP (yellow) (derived from peYFP-C1 and peCFP-1, use of the Cre-loxP system to determine the adult fates
respectively, from Clonetech). The eYFP cassette is of Engrailed-2-expressing cells originating in the mid-
flanked by loxP sites, and the eCFP cassette by FRT brain-hindbrain constriction (Zinyk et al., 1998), and use
sites, such that following the production of transgenic of the Flp-FRT system to analyze the adult expansion
of neural progenitors which transiently express Wnt-1mice, one or the other cassette may be removed by
Review
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Figure 7. Marking Focused Mutagenesis
Screens Using the pCX-YNC Reporter
(A) A traditional hemizygosity screen using
visibly marked chromosomes and deletions.
In this example, an ENU-mutagenized male
(F0) is mated with an eYFP homozygous fe-
male to generate an eYFP-marked F1 female
heterozygous for an ENU-induced mutation
(m). Mutations in the region are uncovered in
a test cross with an eCFP-marked deletion
carrier male. The F2 test class progeny are
color-coded to visually distinguish the test
class (unmarked), mutation carrier (cyan), and
two discard classes (yellow/cyan and yellow).
(B) A hemizygosity screen combining visibly
marked chromosomes, deletions, and ES cell
mutagenesis. ENU- or EMS-mutagenized ES
cell clones are used to produce germline
competent chimeric mice. Mutations in the
region produced in the diploid ES cells resid-
ing on the eCFP-marked chromosome (m1)
and on the unmarked chromosome (m2) are
uncovered in a single-generation test cross
with an eYFP-marked deletion carrier female.
The F1 test class progeny are color-coded to
visually distinguish the m1 test class (cyan),
the m1 carrier (cyan/yellow), the m2 test class
(unmarked), and the m2 carrier (yellow).
(C) A regional homozygosity screen using a
visibly marked, recessive lethal inversion. An
ENU-treated F0 male is mated with a female
heterozygous for a marked inversion chromo-
some. Cre-loxP-mediated chromosome engi-
neering has been used to produce recessive
lethal inversion chromosomes dominantly
marked with the K-14-Agouti transgene (Ag)
(see text). F1 offspring carrying a mutation
(m) and the marked inversion are mated with
an animal carrying both the marked inversion
and eYFP- (or eCFP-) to produce F2 progeny.
F2 mice carrying the mutation balanced by
the marked inversion are selected based on
the absence of yellow (or cyan) fluorescence.
These F2 offspring can be intercrossed to
produce the F3 test class progeny that are
marked to distinguish the homozygous muta-
tion test class (unmarked) and carrier (Ag).
Homozygosity for the marked inversion is le-
thal (l), typically owing to the disruption of
an essential locus at an inversion breakpoint.
This figure is a modified recreation of Figure
4 from Frank et al., 2003.
Developmental Cell
22
Figure 8. Molecular Fate Mapping
Illustration of how site-specific recombination can be used to study the deployment of progenitor cells and their descendants during develop-
ment.
(A) Structure of a Flp-responsive indicator transgene. Flpe-mediated recombination between direct FRT repeats results in deletion of intervening
DNA and restoration of the lacZ open reading frame (rendering cells -gal). Permanent expression of the recombined indicator transgene
requires use of a constitutive, broadly active promoter (BAP).
(B) Development of the neural tube is represented as a simple cylinder. Top row, transient expression profile of hypothetical gene A (purple).
Middle row, transient expression profile of Flpe recombinase (purple) driven by regulatory elements from gene A. Bottom row, switching on
a heritable lacZ (dark blue) lineage tracer by Flpe-mediated excisions. Descendant cells (-gal, depicted here as dark blue circles) are
visualized throughout development.
during embryonic development (Dymecki and Tomasie- reporter gene. Because the excision event activating
the reporter is at the level of chromosomal DNA, it iswicz, 1998). Both systems involve two mouse strains
that are intercrossed: (1) a recombinase mouse, ex- stably inherited to progeny cells, thereby marking these
cells and revealing their contribution to embryonic andpressing Cre or Flp in a gene-specific fashion, and (2) an
indicator mouse, harboring a transgene that “indicates” adult tissues. By delineating the adult structures that
arise from a gene expression domain within the embryo,that a recombination event has occurred and provides
a permanent record of this event by transforming it into such molecular fate maps not only inform develop-
mental processes, but also guide an investigator wherea heritable lineage marker (Figure 8). The basic elements
contained within an indicator transgene are (1) a reporter to look for subtle phenotypes in the adult animal, poten-
tially long after the time of normal expression of thegene, functionally silenced by insertion of a STOP cas-
sette (containing, for instance, a head-to-tail array of mutated gene. (For further review on molecular fate
mapping in the mouse, see Dymecki et al., 2002.)four simian virus 40 (SV40) polyA sequences coupled
with translational stop codons in all reading frames A number of useful indicator mice are available and
are listed in Table 2. Each reporter molecule contained[Maxwell et al., 1989; Soriano, 1999]) that has been either
floxed or flrted; and (2) a widely active promoter capable within the various indicators has a unique advantage.
For example, nuclear-localized-gal facilitates the iden-of driving reporter expression ideally in all cell types
and at all stages of development, such that following a tification of individual cells, human placental alkaline
phosphatase (PLAP) has the potential to provide infor-recombination event in any given cell, that cell and all
progeny cells will be marked regardless of subsequent mation on cell morphology (Fields-Berry et al., 1992),
and green fluorescent protein (GFP) and other color vari-fate specification. In recombinase; indicator doubly
transgenic animals, excision of the STOP cassette in the ant fluorescent proteins can be used to visualize live
cells. Of the listed indicator mice, R26::FLAP (ROS-indicator transgene will occur only in the recombinase-
expressing cells, thereby activating (i.e., repairing) the A26::FRT- and loxP-disrupted PLAP) represents the first
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Table 2. Cre- and Flp-Responsive Indicator Mice
Promoter/ Condition for
Responsive Enhancer Transgenic vs. Reporter
Indicator to: Sequences Knock In Reporter(s) Expression Reference
cAct-XstopXlacZ Cre chicken -actin T nuclear -gal ELC (Tsien et al., 1996)
floxLacZ Cre chicken -actin T -gal ELC (Akagi et al., 1997)
c-STOP-lacZ Cre chicken -actin T nuclear -gal ELC (Zinyk et al., 1998)
R26R Cre ROSA26 KI -gal ELC (Soriano, 1999)
ROSA26flox Cre proviral ROSA26 KI -gal ELC (Mao et al., 1999)
Z/AP Cre CAG T -gal -- (Lobe et al., 1999)
PLAP ELC
UCR Cre G3BP (BT5) KI -gal ELC (Michael et al., 1999)
Z/EG Cre CAG T -gal -- (Novak et al., 2000)
eGFP ELC
CAG-CAT-EGFP Cre CAG T eGFP ELC (Kawamoto et al., 2000)
R26R-EYFP Cre ROSA26 KI eYFP ELC (Srinivas et al., 2001)
R26R-ECFP Cre ROSA26 KI eCFP ELC (Srinivas et al., 2001)
ROSA26-EGFPf Cre ROSA26 KI eGFP ELC (Mao et al., 2001)
LSLMAP2GFP Cre Chicken -actin T MAP2-GFP ELC (Huang et al., 2002)
Hmgcr::FRTZ Flp Hmgcr sequences T nuclear -gal EFC (Rodriguez and Dymecki, 2000)
R26::FRAP Flp ROSA26 KI PLAP EFC (Awatramani et al., 2001)
R26FR Flp ROSA26 KI -gal EFC (Possemato et al., 2002)
R26::FLAP Flp  Cre ROSA26 KI eGFP(F) EFC (Awatramani et al., 2003)
PLAP EFC  ELC
Hmgcr, hydroxymethylglutaryl-coenzyme A reductase; -gal, beta-galactosidase; ELC, excision of loxP-flanked STOP cassette; CAG, chick
-actin promoter coupled with cytomegalovirus enhancer sequences; PLAP, human placental alkaline phosphatase; UCR, universal conditional
lacZ reporter; EYFP, enhanced yellow fluorescent protein; ECFP, enhanced cyan fluorescent protein; EFC, excision of FRT-flanked STOP
cassette; eGFP(F), enhanced green fluorescent protein, farnistylated. Dashed lines indicate constitutive expression of the reporter prior to
recombinase activity.
dual-recombinase-responsive indicator strain (Awa- the contribution of marked neural crest cells to the de-
velopment of craniofacial and cardiac structures couldtramani et al., 2003). Coupled with two recombinase-
expressing alleles, R26::FLAP allows the tracking of be explored carefully in mice for the first time (Chai et
al., 2000; Jiang et al., 2000). Extending this analysis, thecells that have undergone two genetic events in their
history, and therefore is useful for studying many fate of derivatives of cardiac neural crest cells in mice
null for the 1 and  retinoic acid receptors was traced,multistep processes relevant to development and/or
disease. For example, through its application, progeni- revealing that the number, migration, and terminal fate
of these cells is normal in the double mutants (Jiang ettor-specific expression of gene combinations can be
mapped onto specific cell fates, helping to define combi- al., 2002). This study serves to highlight the added utility
of SSR-based molecular fate mapping to track cells innatorial gene expression codes important in the devel-
opment of diverse cell types. Moreover, it represents a mutant backgrounds to determine, for example, if they
assume abnormal cell fates, or migrate to abnormal po-general strategy for intersectional gene activation (IGA),
which could be employed to ectopically express any sitions. In addition, by expressing Flp within the Wnt1
expression domain and permanently marking these Flp-gene of interest solely at the intersection (in space or
time) of two gene expression domains. In most cases, expressing cells and their descendants, it was demon-
strated definitively for the first time that dorsal germinalthis provides great improvement in selectivity, allowing
more precisely defined cell populations to be studied. zones give rise to neurons of the precerebellar afferent
system, a group of ventral brainstem nuclei that provideOne of the first demonstrations of the utility of molecu-
lar fate mapping has been the tracking of cells arising major input to the cerebellum (Rodriguez and Dymecki,
2000; R. Awatramani, C. Rodriguez, and S.M.D., unpub-from the Wnt-1 expression domain. Wnt-1 mRNA is de-
tectable largely within dorsal neuroepithelium of the lished data).
midgestation embryo (Wilkinson et al., 1987), a tissue
that gives rise to a wide variety of migratory cell popula- Conclusion
The completion of the human (Lander et al., 2001; Ventertions over the course of development. These migratory
cell populations include the neural crest and derivatives et al., 2001) and mouse (Lindblad-Toh et al., 2001; Wa-
terston et al., 2002) genome sequencing projects to-of the rhombic lip, the latter referring specifically to
neuroepithelium adjacent to the roof plate of the fourth gether with advances in SSR technology have heralded
a new era of genetic analysis in the mouse. The geneticventricle. Although these Wnt-1-expressing cell popula-
tions have been the subject of many studies, a compre- similarity of mice and humans, the availability of sophis-
ticated SSR-based tools with which to explore genehensive analysis of their terminal fates had not been
possible in mice due to the cells’ extensive migration function, and the genetic tractability of ES cells, make
the mouse a powerful model system. Indeed, with thepatterns and lack of a marker to follow them throughout
development and within the adult. By expressing Cre tools of SSR technology in hand, the field of mouse
genetics is primed to determine the contribution of everywithin the Wnt1 domain and permanently marking these
Cre-expressing cells and their descendants with -gal, human gene to development, disease, and disability.
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